Related references
Note: Only part of the references are listed.Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults
M. J. M. Bonten et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A risk based model for quantifying the impact of information quality
Alexander Borek et al.
COMPUTERS IN INDUSTRY (2014)
High Incidence of Community-Acquired Pneumonia among Rapidly Aging Population in Japan: A Prospective Hospital-Based Surveillance
Masahiro Takaki et al.
JAPANESE JOURNAL OF INFECTIOUS DISEASES (2014)
Relationship between public subsidies and vaccination rates with the 23-valent pneumococcal vaccine in elderly persons, including the influence of the free vaccination campaign after the Great East Japan Earthquake
Toshio Naito et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2014)
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≥50 years An open-label trial
Masanari Shiramoto et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Modeling of Cost Effectiveness of Pneumococcal Conjugate Vaccination Strategies in US Older Adults
Kenneth J. Smith et al.
AMERICAN JOURNAL OF PREVENTIVE MEDICINE (2013)
Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older
Lisa A. Jackson et al.
VACCINE (2013)
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
Lisa A. Jackson et al.
VACCINE (2013)
Vaccines for preventing pneumococcal infection in adults
Sarah Moberley et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2013)
Cost-effectiveness of Adult Vaccination Strategies Using Pneumococcal Conjugate Vaccine Compared With Pneumococcal Polysaccharide Vaccine
Kenneth J. Smith et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Nationwide surveillance of bacterial respiratory pathogens conducted by the Surveillance Committee of Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Clinical Microbiology in 2009: general view of the pathogens' antibacterial susceptibility
Akira Watanabe et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2012)
Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years
Derek Weycker et al.
VACCINE (2012)
Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany
Alexander Kuhlmann et al.
HEALTH ECONOMICS REVIEW (2012)
Results of a Cohort Model Analysis of the Cost-Effectiveness of Routine Immunization With 13-Valent Pneumococcal Conjugate Vaccine of Those Aged ≥65 Years in the Netherlands
Mark H. Rozenbaum et al.
CLINICAL THERAPEUTICS (2010)
Serotype and antibiotic resistance of isolates from patients with invasive pneumococcal disease in Japan
N. Chiba et al.
EPIDEMIOLOGY AND INFECTION (2010)
INTERNATIONAL SURVEY ON WILLINGNESS-TO-PAY (WTP) FOR ONE ADDITIONAL QALY GAINED: WHAT IS THE THRESHOLD OF COST EFFECTIVENESS?
Takeru Shiroiwa et al.
HEALTH ECONOMICS (2010)
A new method to simulate the triangular distribution
William E. Stein et al.
MATHEMATICAL AND COMPUTER MODELLING (2009)
Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: A systematic review of conclusions and assumptions
Isla Ogilvie et al.
VACCINE (2009)
Overview of vaccination policies for the elderly in Western European countries
Sandrine I. Samson et al.
AGING CLINICAL AND EXPERIMENTAL RESEARCH (2009)
Share Paper
